Gilgamesh Pharmaceuticals Stock

Gilgamesh Pharmaceuticals provides medicines for psychedelic, novel psychotropic drugs, depression, anxiety, and stress-related disorders.

Sign up today and learn more about Gilgamesh Pharmaceuticals Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Gilgamesh Pharmaceuticals Stock

Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction and many other devastating diseases. Our purpose is to accelerate treatments and fundamentally improve mental health.

Funding History

July 2020$2.4M
August 2020$125K
May 2021$27.0M
December 2022$39.0M


Board Member

Amy Kruse

Discovery Chemist & Co-Founder

Mike Cunningham

Discovery Chemist & Co-Founder

Andrew Kruegel

CBO and Head of Research

Laszlo Kiss

CEO & Co-Founder

Jonathan Sporn

Preclinical Pharmacologist & Co-Founder

Jeff Witkin

Chief Operating Officer

Yoni Falkson

Chief Scientific Officer & Co-Founder

Dalibor Sames


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: